Fingolimod
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Fingolimod
Fingolimod: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Fingolimod, so there is currently no new predicted indication. The uses recorded for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| multiple sclerosis | licence in another country |
| relapsing-remitting multiple sclerosis | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11818B | Gilenya | Capsule 250 micrograms (as hydrochloride | Valid |
Safety Considerations
The TGA-approved Product Information (PI) warnings and contraindications were not available in the data compiled for this report. Please refer to the PI for full safety information.
Contraindications suggested by the knowledge graph (drug-disease links in the TxGNN knowledge graph, not label text):
- Liver failure, kidney disease, pyoureter
- Diabetes mellitus, diabetic ketoacidosis
- Lung disease
- Leukopenia
- Uveitis, iris disease, ciliary body disease, panuveitis, macular oedema (retinal and cystoid)
- Atrioventricular block, sick sinus syndrome (including the familial form)
Drug interactions (100 interactions were recorded; the main ones are listed):
- Major:
- Corticosteroids: hydrocortisone, prednisone, dexamethasone, betamethasone, budesonide, triamcinolone (including ophthalmic)
- QT-prolonging or related agents: clarithromycin, levofloxacin, ondansetron, dolasetron, palonosetron, cisapride
- Moderate: famotidine, ranitidine, cimetidine, nizatidine, loperamide, naltrexone
- Minor: metronidazole
Fingolimod causes lymphocyte sequestration, so immunosuppression and infection risk are relevant to any oncology use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.